Guillain-Barré Syndrome, or GBS, is a rare but serious neurological disorder that can cause sudden muscle weakness or flaccid paralysis. Although uncommon, the condition is an important cause of acute flaccid paralysis worldwide and can affect people of all ages.
Recognizing the condition and classifying cases consistently is important for both clinical care and vaccine safety monitoring. To support this, the Brighton Collaboration developed a standardized case definition that helps clinicians and researchers identify and classify cases of Guillain-Barré syndrome in a consistent way.
🎥 Watch the video: Understanding Guillain-Barré Syndrome and the Brighton Case Definition
What Is Guillain-Barré Syndrome?
GBS is an autoimmune disorder in which the body’s immune system mistakenly attacks the peripheral nerves. Damage to these nerves disrupts communication between the brain and muscles, leading to progressive weakness.
Symptoms typically begin with tingling or weakness in the legs and may progress upward to affect the arms, facial muscles, or breathing muscles in severe cases. The condition generally progresses from first symptoms to peak severity within 12 hours to four weeks.
Who Is Affected?
GBS can occur in people of all ages, from children to older adults, and occurs globally. In many countries, it has become the leading cause of acute flaccid paralysis.
Most individuals with GBS report a gastrointestinal or respiratory infection in the weeks prior to symptom onset, suggesting that infections can trigger the abnormal immune response.
How Is GBS Diagnosed?
Diagnosis is based primarily on clinical features, including:
- Weakness affecting both sides of the body
- Reduced or absent deep tendon reflexes
- A characteristic progression of symptoms over time
Additional diagnostic tests may support the diagnosis, including cerebrospinal fluid (CSF) analysis and electrophysiological studies that evaluate nerve function.
Why Standardized Case Definitions Matter
To support consistent diagnosis and monitoring, the Brighton Collaboration developed a standardized case definition for Guillain-Barré syndrome.
The case definition includes three levels of diagnostic certainty:
Level 3 – Possible case
Based on the characteristic clinical presentation alone.
Level 2 – Probable case
Clinical features plus either cerebrospinal fluid findings or electrophysiological evidence.
Level 1 – Definite case
Clinical features supported by both cerebrospinal fluid findings and electrophysiological testing.
Supporting Global Vaccine Safety Monitoring
Because GBS has occasionally been reported following immunization, consistent case identification is important for monitoring potential adverse events following vaccination.
Standardized case definitions allow researchers, clinicians, and regulators to classify cases consistently across countries and studies—strengthening global vaccine safety surveillance and improving confidence in vaccine safety systems.
Educational resources like this video help clinicians and public health professionals better understand GBS and apply standardized definitions in research and surveillance.
